Patient preferences in chronic immune-mediated inflammatory diseases potentially treated with biological drugs: discrete choice analysis using real-world data analysis

References

• Abbafati C, Abbas KM, Abbasi-Kangevari M, et al. Global burden of 369 Diseases and Injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct;396(10258):1204–1222.
   PubMed Web of Science ®Google Scholar
• Kuenzig ME, Benchimol EI, Lee L, et al. The impact of inflammatory bowel disease in Canada 2018: direct costs and health services utilization. J Can Assoc Gastroenterol. 2019 Feb;2(Supplement_1):S17–33.
   PubMedGoogle Scholar
• Burisch J, Vardi H, Pedersen N, et al. Costs and resource utilization for diagnosis and treatment during the initial year in a European inflammatory bowel disease inception cohort: an ECCO-EpiCom study. Inflamm Bowel Dis. 2015 Jan;21(1):121–131.
   PubMed Web of Science ®Google Scholar
• Burisch J, Vardi H, Schwartz D, et al. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study. Lancet Gastroenterol Hepatol. 2020 May;5(5):454–464.
   PubMed Web of Science ®Google Scholar
• Chaparro M, Barreriro-de Acosta M, Benítez J, et al. Epidemiology, clinical characteristics, evolution and treatments in newly diagnosed inflammatory bowel disease (IBD): results from the nationwide EpidemIBD study of GETECCU. 15th Congress Of ECCO- European Crohn’s And Colitis Organisation. 2020;14(Supplement_1):S594–S597. doi: 10.1093/ecco-jcc/jjz203.872
   Google Scholar
• Fernández A, Hernández V, Martínez-Ares D, et al. Incidence and phenotype at diagnosis of inflammatory bowel disease. Results in Spain of the EpiCom study. Gastroenterol Hepatol. 2015 Nov;38(9):534–540.
   PubMed Web of Science ®Google Scholar
• López-Medina C, Molto A, Sieper J, et al. Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study. RMD Open. 2021 Jan;7(1):e001450.
   PubMed Web of Science ®Google Scholar
• Brunet E, Vela E, Melcarne L, et al. Time trends of crohn’s disease in Catalonia from 2011 to 2017. increasing use of biologics correlates with a reduced need for surgery. J Clin Med. 2020 Sep;9(9):2896.
   PubMed Web of Science ®Google Scholar
• Calleja-Hernández MÁ, Martínez-Sesmero JM, Santiago-Josefat B. Biosimilars of monoclonal antibodies in inflammatory diseases and cancer: current situation, challenges, and opportunities. Farm Hosp. 2020 Jun;44(3):100–108. doi: 10.7399/fh.11280
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Revised framework for interaction between the European Medicines Agency and patients and consumers and their organisations. EMA/637573/2014. 2014.
   Google Scholar
• Reed SD, Reaney M, Shuren J, et al. Examining the role of patient preferences to inform regulatory decisions. Baltimore: MD: ISPOR; 2018.
   Google Scholar
• Elstein AS, Chapman GB, Chmiel JS, et al. Agreement between prostate cancer patients and their clinicians about utilities and attribute importance. Health Expect. 2004 Jun; 7(2):115–125. InternetAvailable from http://www.ncbi.nlm.nih.gov/pubmed/15117386
   PubMed Web of Science ®Google Scholar
• Chapman GB, Elstein AS, Kuzel TM, et al. Prostate cancer patients’ utilities for health states: how it looks depends on where you stand. Med Decis Making. 1998;18(3):278–286. InternetAvailable from: http://www.ncbi.nlm.nih.gov/pubmed/9679992
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQoL) measures in the evaluation of medicinal products. EMEA/CHMP/EWP/139391/2004. London; 2005.
   Google Scholar
• U.S. Department of Health and Human Services. Food and Drugs Administration C for DE and R (CDER). Guidance for industry and FDA Staff. Qualification process for drug development tools. Silver Spring: MD: U.S. Department of Health and Human Services; 2014.
   Google Scholar
• European Medicines Agency. Patients’ and Consumers’ Working Party.
   Google Scholar
• Levitan B, Getz K, Eisenstein EL, et al. Assessing the financial value of patient engagement: a quantitative approach from CTTI’s patient groups and clinical trials project. Ther Innov Regul Sci. 2018 Mar;52(2):220–229.
   PubMed Web of Science ®Google Scholar
• Lloyd HM, Pearson M, Sheaff R, et al. Collaborative action for person-centred coordinated care (P3C): an approach to support the development of a comprehensive system-wide solution to fragmented care. Health Res Policy Syst. 2017 Nov;15(1):98.
   PubMedGoogle Scholar
• Wagner EH, Bennett SM, Austin BT, et al. Finding common ground: patient-centeredness and evidence-based chronic illness care. J Altern Complement Med. 2005 Dec;11(supplement 1):s-7-s–15.
   Google Scholar
• Wagner EH, Austin BT, Davis C, et al. Improving chronic illness care: translating evidence into action. Health Aff. 2001;20(6):64–78. doi: 10.1377/hlthaff.20.6.64
   PubMed Web of Science ®Google Scholar
• Wagner EH. Effective teamwork and quality of care. Med Care. 2004;42(11):1037–1039.
   Google Scholar
• Janssens R, Russo S, van Overbeeke E, et al. Patient preferences in the medical product life cycle: what do stakeholders think? Semi-structured qualitative interviews in Europe and the USA. Patient. 2019 Oct;12(5):513–526.
   PubMedGoogle Scholar
• Ortega F, Otero A, Crespo JF, et al. Satisfaction and adherence with immunosuppressant treatment in renal transplant patients living with a working graft. J Nephrol. 2013;26(2):297–305. doi: 10.5301/jn.5000132
   PubMed Web of Science ®Google Scholar
• Torrance WG. Social preferences for health states: an empirical evaluation of three measurement techniques. Socioecon Plann Sci. 1976;10(3):129–136. doi: 10.1016/0038-0121(76)90036-7
   Web of Science ®Google Scholar
• de Bekker-Grob EW, Donkers B, Jonker MF, et al. Sample size requirements for discrete-choice experiments in healthcare: a practical guide. Patient. 2015 Oct;8(5):373–384. doi: 10.1007/s40271-015-0118-z
   PubMedGoogle Scholar
• Mira JJ, Nuño-Solinís R, Guilabert-Mora M, et al. Development and validation of an instrument for assessing patient experience of chronic illness care. Int J Integr Care. 2016 Aug;16(3):13.
   PubMed Web of Science ®Google Scholar
• NHS. Outpatients Questionnaire. 2011; Available from: https://sp.ukdataservice.ac.uk/doc/5091/mrdoc/pdf/5091userguide2003.pdf
   Google Scholar
• Bridges JFP, Hauber AB, Marshall D, et al. Conjoint analysis applications in health - a checklist: a report of the ISPOR good research practices for conjoint analysis task force. Value Heal. 2011;14(4):403–413. doi: 10.1016/j.jval.2010.11.013
   PubMed Web of Science ®Google Scholar
• Johnson FR, Lancsar E, Marshall D, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force. Value Heal. 2013 Jan;16(1):3–13.
   PubMed Web of Science ®Google Scholar
• Ghazal S, Cokely ET, Garcia-Retamero R. Predicting biases in very highly educated samples: numeracy and metacognition. Judgm Decis Mak. 2014. 9.
   PubMed Web of Science ®Google Scholar
• Carlsson F, Martinsson P. Design techniques for stated preference methods in health economics. Health Econ Internet. 2003 Apr;12(4):281–294. Available from. doi: 10.1002/hec.729
   PubMed Web of Science ®Google Scholar
• Kemp K, Griffiths J, Campbell S, et al. An exploration of the follow-up up needs of patients with inflammatory bowel disease. J Crohns Colitis. 2013 Oct;7(9):e386–95.
   PubMed Web of Science ®Google Scholar
• Casellas F, Ginard D, Riestra S. Patient satisfaction in the management of mild-to-moderate ulcerative colitis: results of a Delphi study among patients and physicians. Dig Liver Dis. 2016 Oct;48(10):1172–1179. InternetAvailable from. https://linkinghub.elsevier.com/retrieve/pii/S1590865816305126
   PubMedGoogle Scholar